Prof Rowan Chlebowski speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the influence of oestrogen plus progestin compared with oestrogen alone use on the incidence of breast cancer.
He outlines the design of this study, which uses data from two randomised, prospective clinical trials. These trials assessed equine oestrogens (CEE) plus medroxy progesterone acetate (MPA) versus CEE alone or placebo in post-menopausal women with breast cancer after a median follow up of 19.2 years.
Prof Chlebowski reports that there was an increased incidence of breast cancer in the population who received CEE plus MPA, along with an increased rate of mortality. In contrast, decreased breast cancer incidence was seen in patients who received CEE alone.
In light of these main findings, he believes these results should impact current guidelines, risk-reduction strategies and ultimately treatment.
Watch the press conference here
Read more about the study here